NEW HAVEN, Conn., June 23, 2017 /PRNewswire/ -- (NYSE: BHVN)
Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) today
announced that it has been added to the Russell
Microcap® Index as part of the Russell indexes
annual reconstitution. The newly reconstituted indexes took effect
following the market close today.
As a member of the Russell Microcap® Index,
Biohaven's common shares will be automatically included in the
appropriate growth and value style indexes. Membership for the
Russell indexes is determined primarily by objective,
market-capitalization rankings and style attributes.
"We are excited about the addition of Biohaven to the Russell
Microcap Index. The Russell U.S. Indexes are the leading U.S.
equity benchmarks for institutional investors. Our inclusion in
this index as a newly public company is a step forward in our
company's development and raises the visibility of our efforts to
bring novel treatments to patients," said Vlad Coric, M.D., Chief Executive Officer at
Biohaven.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $8.4 trillion in assets are benchmarked against
Russell's US indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
More information on the Russell Microcap® Index and
the Russell indexes reconstitution can be found in the "Russell
Reconstitution" section of the FTSE Russell website.
About Biohaven
Biohaven is a clinical-stage biopharmaceutical company with a
portfolio of innovative, late-stage product candidates targeting
neurological diseases, including rare disorders. Biohaven has
combined internal development and research with intellectual
property licensed from companies and institutions including
Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and
Massachusetts General Hospital. Currently, Biohaven's lead
development programs include multiple compounds across its CGRP
receptor antagonist and glutamate modulation platforms.
Biohaven's common shares are listed on the New York Stock Exchange
and traded under the ticker symbol BHVN. More information
about Biohaven is available at www.biohavenpharma.com.
About FTSE Russell
FTSE Russell is a leading global index provider creating and
managing a wide range of indexes, data and analytic solutions to
meet client needs across asset classes, style and strategies.
Covering 98% of the investable market, FTSE Russell indexes offer a
true picture of global markets, combined with the specialist
knowledge gained from developing local benchmarks around the
world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$12.5 trillion is currently
benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, exchange-traded fund (ETF) providers
and investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group.
For more information, visit www.ftserussell.com
Contact
Dr. Vlad Coric
Chief Executive Officer
Biohaven Pharmaceutical Holding Company Ltd.
Phone: (203) 404-0410
Email: vlad.coric@biohavenpharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biohaven-added-to-russell-microcap-index-300479100.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.